The prevalence of BC in our neonatal screening cohort of TP53 p.R337H carriers and noncarriers (2006–2018, Group 1) and the BC mortality rates reported for other unknown women from the public database (Group 2) were evaluated in each subregion to estimate BC risk. Here, TP53 is linked to breast cancer.